Pharmabiz
 

NPPA revises prices of 87 formulations

Our Bureau, New DelhiFriday, May 30, 2003, 08:00 Hrs  [IST]

The National Pharmaceutical Pricing Authority (NPPA) has revised/fixed the prices of 87 formulation packs on May 27, 2003. The companies whose products that have come under price revision are Cadila Pharma (Pvt.) Ltd, Dr. Reddy's Labs Ltd, Centaur Labs Pvt. Ltd, Glenmark Pharma, Neo Pharma, Brown & Burk Pvt Ltd, Unimerk, Jenburkt, Glaxo India Limited, Mercury Pharma Industries, Alpine Labs and Wockhardt Pvt. Ltd. The prices have been fixed for the first time in the case of 3 formulation packs. In the case of 82 packs the price have been reduced ranging from 0.11% to 67.33%. The revision in prices was warranted due to downward revision in price of scheduled bulk drug. In the case of 2 packs the price have been increased ranging from 2.43% to 14.90% due to upward revision in the prices of raw materials. Of the 87 formulation packs, ceiling prices (exclusive of excise duty and local taxes etc.) have been fixed in respect of 60 packs which are applicable to all the manufacturers of all such formulations including SSI Units. The non-ceiling prices (inclusive of excise duty but exclusive of local taxes etc.) have been fixed in respect of 27 packs. The prices have been fixed/revised in accordance with the provisions of the Drugs Price Control Order (DPCO), 1995 and as per the established criteria and guidelines. A copy of the statement showing the existing (where available) and revised prices is enclosed herewith. The formulations for which prices have been revised/fixed are Cefazolin formulations used as broad spectrum Anti-biotic, Chlorpromazine formulation used in the treatment of anxiety disorders, Dexamethasone based formulations used in the treatment of allergic reactions, Gentamycin Sulphate based formulation used in the treatment of burns, urinary tract infections, Levodopa and Carbidopa based formulation used in treatment of Parkinson disease, Streptomycin and Penicillin based formulation used in treatment of streptococcal and Pneumococcal infections, Sulphadoxine and Pyramethamine based formulation used in treatment of malaria, Oxytetracycline and Tetracycline based formulation used in treatment of mixed bacterial infections. The prices of Vitamins formulation used in the treatment of diseases caused by deficiency of vitamins and Insulin formulations used in treatment of diabetics have also been fixed.

 
[Close]